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OBJECTIVE This study was performed to evaluate the recent changes in the outcome of coronary
interventions in patients with unstable angina (UA).
BACKGROUND An early invasive strategy has not been shown to be superior to conservative treatment in
patients with UA. Earlier studies had utilized older technology. Interventional approaches
have changed in the recent past, but to our knowledge, no large studies have addressed the
impact of these changes on the outcome of coronary interventions.
METHODS We analyzed the in-hospital and intermediate-term outcome in 7,632 patients with UA who
underwent coronary interventions in the last two decades. The study population was divided
into three groups: group 1, n 5 2,209 who had coronary intervention from 1979 to 1989;
group 2, n 5 2,212 with interventions from 1990 to 1993; and group 3, n 5 3,211 treated
from 1994 to 1998.
RESULTS Group 2 and 3 patients were older and sicker compared with group 1 patients. The clinical
success improved significantly in group 3 (94.1%) compared with group 2 (87%) and group
1 (76.5%) (p , 0.001). There was a significant reduction in in-hospital mortality, Q-wave
myocardial infarction and need for emergency bypass surgery in group 3 compared with the
earlier groups. One-year event-free survival was also significantly higher in the recent group
compared with the earlier groups: 77% in group 3, 70% in group 2 and 74% in group 1 (p ,
0.001). With the use of multivariate models to adjust for clinical and angiographic variables,
treatment during the most recent era was found to be independently associated with improved
in-hospital and intermediate-term outcomes.
CONCLUSIONS There has been significant improvement in the in-hospital and intermediate-term outcome of
coronary interventions in patients with UA in recent years; newer trials comparing
conservative and invasive strategies are therefore needed. (J Am Coll Cardiol 2000;36:
674–8) © 2000 by the American College of Cardiology
An early aggressive approach for the treatment of unstable
angina (UA) has not been found to be superior to a
conservative strategy (1–3). However, interventional ap-
proaches have changed significantly in the recent years. Use
of glycoprotein IIb/IIIa inhibitors has improved the out-
come of angioplasty in patients with UA (4–6), and
placement of stents has reduced the frequency of in-hospital
adverse events as well as improved the restenosis rates (7,8).
These two advances have significantly improved the out-
come of coronary interventions in patients with UA, ren-
dering previous conclusions of the relative roles of an
aggressive versus conservative approach less applicable to
today’s practice. In addition, new interventional devices and
adjunctive medical therapies have come into practice in the
recent years. To our knowledge, no large studies have
addressed the issue of the changing technology on the
outcome of coronary interventions in patients with UA.
Our principal objective was to evaluate changes in the
early- and intermediate-term outcomes of patients with UA
undergoing coronary intervention over two decades.
METHODS
Study patients. Patients undergoing percutaneous revascu-
larization at the Mayo Clinic have been followed up
prospectively since 1979 in accord with an Institutional
Review Board approved protocol. A total of 7,632 patients
who underwent coronary intervention with the diagnosis of
UA in the last 20 years were included in this study. Patients
were divided into three groups. Group 1 comprised 2,209
patients who underwent coronary intervention from 1979 to
1989. In this era, the technology of percutaneous translu-
minal coronary angioplasty was evolving and operator expe-
rience in coronary interventions was increasing. Group 2
consisted of 2,212 patients who underwent coronary inter-
ventions from 1990 to 1993. In this transition period, the
operator experience was greater, but stents were available
only on an investigational basis and were used infrequently.
Group 3 consisted of 3,211 patients treated from 1994 to
1998. In this recent era, there was more frequent use of
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stents and glycoprotein IIb/IIIa inhibitors as well as much
greater operator experience.
Definitions. Unstable angina was defined as new onset of
chest pain at rest or progression of stable angina to an
increased class (Canadian Heart Classification) within two
months of coronary intervention, the last episode of pain
occurring within one week of the procedure. Any ischemic
pain after myocardial infarction (MI) was also considered to
represent UA. Clinical success was defined as a reduction of
residual luminal diameter stenosis to ,50% on the basis of
visual assessment of orthogonal views without in-hospital
death, Q-wave MI or need for emergency coronary artery
bypass surgery. In-hospital mortality was defined as death
from any cause occurring during the same hospitalization as
that in which the coronary intervention was performed.
Periprocedural MI was defined as chest pain with devel-
opment of new Q-wave on electrocardiogram (ECG).
Myocardial infarction on follow-up was defined as chest
pain with either increase in creatine kinase concentration to
at least two times the upper limit of normal with a positive
MB fraction or new Q waves on the ECG after angioplasty.
Three-vessel disease was defined as diameter stenosis of
$70% in all three epicardial coronary arteries or major
branches thereof. Repeat revascularization was defined as
any subsequent revascularization following coronary inter-
vention in any vessel.
Follow-up. Research coordinators contacted all patients
after hospital discharge at six months and annually thereaf-
ter. The Mayo Clinic hospital records of patients who
suffered an event during follow-up were reviewed. The
medical records of patients suffering adverse events at other
hospitals were also obtained and reviewed.
Statistical analysis. The univariate associations between
discrete baseline and complication data were tested for
overall group. One-way analysis of variance was used to test
for differences in continuous variables. Stepwise logistic
regression was used to develop multivariate models for
in-hospital mortality and for the composite end point of
in-hospital death, MI or repeat revascularization. A dichot-
omous variable for each of the last named two time periods
was added to the model. Results are presented as odds ratio
with 95% confidence intervals (CIs). Cox proportional
hazards models were developed for patients who had suc-
cessful interventions, for the end point of postdischarge
death, death or MI, and the composite end point of death,
MI or repeat revascularization. The variables representing
the year groups were forced into the model. Results are
presented as relative risk ratios with corresponding CIs.
Estimated event-free survival curves were calculated from
these models for each of the end points. All covariates, with
the exception of the year group variables, were fixed at their
mean value; the year group was set to represent each of the
time periods.
RESULTS
Baseline characteristics. Clinical and baseline characteris-
tics of the three groups are shown in Table 1. The mean age
of group 2 and 3 patients was significantly older than that of
group 1. The prevalence of other adverse cardiovascular risk
factors, including diabetes and hypertension at presentation
and prior coronary artery bypass surgery, was significantly
higher in the recent time period as compared with earlier
time periods (p , 0.001). Three-vessel disease was equally
prevalent in all three groups.
Procedural practice. The use of balloon angioplasty alone
in the treatment of UA decreased by 60% across the three
time periods and the use of stents increased from zero before
1990 to 51.4% of all the procedures in the last four years
(Table 2). Atherectomy was used in 62 (2.8%) patients (3
transluminal extraction catheter, 59 directional coronary
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Table 1. Baseline Characteristics
Variable
Group 1
(1979–1989)
n 5 2,209 (%)
Group 2
(1990–1993)
n 5 2,212 (%)
Group 3
(1994–1998)
n 5 3,211 (%) p Value
Age, yr (mean 6
SD)
62.1 6 11.1 64.8 6 11.2 64.6 6 12.0 , 0.001
Male 1,572 (71.2) 1,569 (70.9) 2,222 (69.2) 0.2
Diabetes mellitus 292 (13.3) 440 (19.9) 661 (20.6) , 0.001
Hypertension 1,008 (45.9) 1,076 (49) 1,835 (57.8) , 0.001
Prior CABG 280 (12.7) 500 (22.6) 671 (20.9) , 0.001
Three-vessel disease 627 (29) 629 (29.2) 903 (29.5) 0.9
CHF (ever
occurred)
203 (9.2) 248 (11.3) 376 (11.9) 0.009
Thrombus 661 (29.9) 908 (41.1) 1099 (34.2) 0.001
LVEF #40% 154 (6.9) 70 (3.1) 251 (7.8) 0.001
CHC 3 or more 1,938 (87.7) 1,884 (85.2) 2,266 (70.6) 0.001
MI 1–7 d 326 (14.8) 366 (16.6) 489 (15.2) 0.2
MI ,24 h 305 (13.8) 301 (13.6) 356 (11.1) 0.003
CABG 5 coronary artery bypass grafting; CHC 5 Canadian heart classification; CHF 5 congestive heart failure; LVEF 5 left ventricular ejection fraction; MI 5 myocardial
infarction.
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atherectomy) in group 1; 180 (8.1%) patients in group 2
(160 directional coronary atherectomy, 16 rotational
atherectomy, 4 transluminal extraction catheter); and 344
(10.7%) in group 3 (245 rotational atherectomy, 66 direc-
tional coronary atherectomy, 35 transluminal extraction
catheter procedures). The use of the glycoprotein IIb/IIIa
inhibitor, abciximab, increased over the last few years; it was
used in 34.5% of patients in the most recent cohort.
In-hospital outcome. Procedural outcomes significantly
improved with time (Table 3). Clinical success rates in the
most recent era were significantly higher. The clinical
success in group 3 was 94.1% compared with 87% in group
2 and 76.5% in group 1 (p , 0.001). A significant reduction
in mortality was observed in patients with UA treated with
coronary interventions in the last four years compared with
earlier time periods. Mortality was 3% in group 1, 2.4% in
group 2 and 1.8% in group 3 (p 5 0.009). There was also a
significant reduction in the incidence of Q-wave MI and the
need for emergency coronary artery bypass surgery in group
3 as compared with groups 1 and 2.
The correlates of in-hospital mortality and composite end
points on multivariate logistic regression analysis are pre-
sented in Table 4. After adjustment for these baseline and
angiographic variables, patients treated in the recent time
period had a significantly lower in-hospital mortality com-
pared with early groups (odds ratio, 0.5; 95% CI, 0.3 to 0.7;
p , 0.001) (Table 4). Similarly, treatment era was corre-
lated with a lower incidence of in-hospital death, MI,
coronary artery bypass surgery or need of repeat coronary
angioplasty. Group 3 demonstrated significant improve-
ment in the composite end points in comparison with group
1 (odds ratio, 0.34; 95% CI, 0.28 to 0.41; p , 0.001)
(Table 5).
Event-free survival after hospital discharge. Follow-up
was complete in 100% of group 1 and 2 patients and 93% of
group 3 patients. Follow-up data were analyzed for patients
who had a successful coronary intervention. The mean
follow-up was 9.4 6 3.6 years for group 1 patients, 5.2 6
1.8 years for group 2 patients and 1.7 6 1.2 years for group
3 patients. After adjustment for the other significant factors,
the risk of death for the 1994 to 1998 cohort (group 3)
relative to the 1979 to 1989 cohort (group 1) was 0.67 (0.54
to 0.84, p , 0.001), and the risk for the 1990 to 1993 cohort
(group 2) relative to the 1979 to 1989 cohort (group 1) was
0.87 (0.74 to 1.02, p 5 0.08). These results are displayed in
Figure 1. Estimated one-year event-free survival curves for
death and MI based on the Cox proportional hazards model
are shown in Figure 2. The risk of death or MI for group 3
relative to group 1 was 0.82 (0.70 to 0.97, p 5 0.02), and for
group 2 compared with group 1, 0.96 (0.84 to 1.09, p 5
0.53). Figure 3 shows the estimated event-free survival
curves for death, MI, coronary artery bypass surgery or
repeat revascularization. Estimated event-free survival for
group 3 relative to group 1 was 0.85 (0.76 to 0.94, p 5
0.002). Similar estimated event-free survival for group 2
relative to group 1 was 1.07 (0.97 to 1.17, p 5 0.14).
DISCUSSION
This study demonstrated marked improvement in the in-
hospital and intermediate-term outcome of coronary inter-
ventions in patients with unstable angina in the most recent
era. Greater operator experience, technical improvements in
angioplasty equipment and improvement in medical therapy
Table 2. Procedural and Adjunctive Therapy
Group 1
(1979–1989)
(n) (%)
Group 2
(1990–1994)
(n) (%)
Group 3
(1994–1998)
(n) (%)
Total procedures 2,209 (28.9) 2,212 (29.0) 3,211 (42.1)
PTCA alone 2,117 (95.8) 1,796 (81.2) 1,184 (36.9)
Atherectomy 6 PTCA 62 (2.8) 180 (8.1) 344 (10.7)
Laser 6 PTCA 29 (1.3) 105 (4.7) 15 (0.5)
Stent implantation 1 121 (5.5) 1,649 (51.4)
Combined procedure 0 (0.0) 25 (1.1) 188 (5.9)
Abciximab use NA NA 1,082 (34.5)
NA 5 not available; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 3. Procedural Results After Coronary Intervention Stratified by Era
Group 1
(1979–1989)
n 5 2,209
(n) (%)
Group 2
(1990–1993)
n 5 2,212
(n) (%)
Group 3
(1994–1998)
n 5 3,211
(n) (%) p Value
Clinical success 1,689 (76.5) 1,925 (87) 3,020 (94.1) , 0.001
In-hospital death 67 (3.0) 54 (2.4) 57 (1.8) 0.009
QMI 39 (1.8) 22 (1.0) 24 (0.7) 0.002
Emergency CABG 108 (4.9) 40 (1.8) 21 (0.7) , 0.001
CABG 5 coronary artery bypass grafting; QMI 5 Q-wave myocardial infarction.
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likely contributed to the improved outcomes, which oc-
curred despite a higher risk profile of the treated patients.
Comparison with previous studies. In none of the pub-
lished randomized trials of an early invasive strategy had the
newer treatment strategies, including glycoprotein IIb/IIIa
inhibitors and intracoronary stents, been in use to a signif-
icant degree. Moreover, in the Thrombolysis in Myocardial
Infarction (TIMI) IIIB trial, ,10% of patients had three-
vessel disease; in contrast, in the current study, 29% had
triple-vessel disease. In addition, patients in the recent
cohort in this study were older and sicker. Despite this, the
in-hospital death and MI rates were higher in TIMI IIIB
study—3.2%, compared with 2.5% in the recent group in
our study. This highlights the improvement in the results of
coronary interventions in this high-risk group in the recent
years. The Veterans Affairs Non–Q-Wave Infarction Strat-
egies in Hospital (VANQWISH) trial compared the inva-
sive and the conservative strategy in patients with acute
non–Q-wave MI (1). There was high mortality (11.6%)
after coronary artery bypass surgery and the two revascular-
ization strategies of bypass surgery and percutaneous revas-
cularization were combined in this trial, and the outcome
weighed in favor of conservative strategy (1). There was no
mortality after coronary angioplasty in the early invasive
arm. Moreover, there was no difference in the long-term
event-free survival in the two groups. In the Organization to
Assess Strategies for Ischemic Syndrome (OASIS) registry,
there was no significant difference in rates of cardiovascular
death or MI at seven days and six months in countries with
highest rates of invasive procedures (3). However, the rates
of refractory angina and readmission to the hospital for UA
were significantly lower in the countries with highest rates
of revascularization procedures. Recently, the preliminary
results of the Fast Revascularization During Instability in
Coronary Artery Disease (FRISC II) study were presented
which documented improved outcome in men treated with
an early aggressive strategy (9).
In a 10-year follow-up study of coronary interventions in
patients with UA, it was demonstrated that the early
mortality in patients with UA was higher but the long-term
overall and event-free survival was similar to patients in
whom the diagnosis at the time of intervention was chronic
stable angina (10). This highlights the importance of
improvement in the clinical success and in the lowering of
in-hospital complication rates associated with coronary
interventions in patients with UA. The most recent group in
the current study underscores the significance of the im-
provement in the clinical success and lowering of in-hospital
complications. Improved results with coronary interventions
in the last four years could be because of variety of reasons.
Figure 1. Estimated survival curves for mortality for each of the time
periods based on the Cox proportional hazard model. Risk of 1994 to 1998
relative to 1979 to 1989 is 0.67, p , 0.001. Risk of 1990 to 1993 relative
to 1979 to 1989 is 0.87, p 5 0.08.
Figure 2. Estimated event-free survival curves for death and myocardial
infarction (MI): 1994 to 1998 relative to 1979 to 1989 is 0.82, p 5 0.02.
Risk of 1990 to 1993 relative to 1979 to 1989 is 0.96, p 5 0.53.
Table 4. Correlates of In-Hospital Mortality
p Value
Odds Ratio
(95% CI)
MI ,24 h , 0.001 4.7 (3.1–7.1)
Current CHF , 0.001 2.8 (1.9–4.0)
MI within 1–7 d , 0.001 2.2 (1.5–3.3)
Ejection fraction ,0.40 , 0.001 2.5 (1.5–4.1)
Multivessel disease , 0.001 2.4 (1.5–3.7)
Thrombus 0.002 1.8 (1.2–2.7)
Age* , 0.001 1.8 (1.6–2.2)
CHC $3 0.03 2.0 (1.1–3.7)
Group 2 (1990–1993) , 0.001 0.5 (0.3–0.7)
Group 3 (1994–1998) , 0.001 0.5 (0.3–0.7)
*Represents the odds of a 10-year change in age.
CHC 5 Canadian heart classification; CHF 5 congestive heart failure; CI 5
confidence interval; MI 5 myocardial infarction.
Table 5. Correlates of In-Hospital Death, MI, Coronary Artery
Bypass Grafting, Repeat Percutaneous Revascularization
p Value
Odds Ratio
(95% CI)
MI , 24 h , 0.001 2.2 (1.8–2.8)
Thrombus , 0.001 1.7 (1.5–2.1)
Current CHF , 0.001 1.6 (1.2–2.1)
Multivessel disease , 0.001 1.4 (1.2–1.7)
Age* , 0.001 1.2 (1.1–1.3)
MI 1–7 d 0.05 1.2 (1.0–1.5)
Group 2 (1990–1993) , 0.001 0.6 (0.5–0.7)
Group 3 (1994–1998) , 0.001 0.34 (0.28–0.41)
*Represents the odds of a 10-year change in age.
CHF 5 congestive heart failure; CI 5 confidence interval; MI 5 myocardial
infarction.
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Major advances in the pharmacologic therapy were made
during that period. Abciximab, a glycoprotein IIb/IIIa
inhibitor, came into broad use in the last three years. The
major trials of glycoprotein IIb/IIIa inhibitors during per-
cutaneous coronary interventions in patients with UA have
shown convincing benefits in terms of reduction in the
composite end points including death, MI or emergency
bypass surgery and the benefits were sustained at six months
and three years (4–6). Stents were used in .50% of patients
in group 3. The safety of stents in the presence of thrombus-
containing lesions in patients with UA (generally present in
patients with UA) has been a source of concern. With the
advent of effective antiplatelet therapy, the risk of subacute
thrombosis has been dramatically reduced in patients with
UA, and even in patients with acute MI. Studies of primary
angioplasty utilizing stents in patients with acute MI have
shown that stents are safe even in this setting in which
virtually all patients have intraluminal thrombus (7,8).
Study limitations. This study is a retrospective analysis of
a study population enrolled over a period of 20 years so all
the inherent limitations of a retrospective study need to be
considered. It is difficult to determine the relative impor-
tance of better operator skills, improvement in technology,
use of stents, improved antiplatelet and other adjunctive
therapy in improving the results in the most recent period.
Another limitation is that cardiac enzyme levels were not
routinely measured after a clinically successful angioplasty
and were measured in only clinically indicated situations.
We did not subdivide the patients into categories of UA
with different prognostic implications. However, we never-
theless believe that given the substantial improvement in
outcome of coronary interventions in the recent era, it
would be prudent to perform new trials of percutaneous
coronary interventions versus medical therapy in patients
with UA that include the recent advances in coronary
interventions. Moreover, no comparison was made between
medically and surgically treated patients who presented with
UA.
CONCLUSIONS
This study documents improvement in the in-hospital and
long-term outcome in patients with UA undergoing percu-
taneous coronary interventions since the advent of coronary
angioplasty. This improvement occurred despite the fact
that patients undergoing percutaneous coronary interven-
tions in the recent years tend to be older and sicker. This
demonstrable improvement in the recent time period should
rekindle the debate between an early aggressive intervention
and a conservative approach in the treatment of patients
with UA.
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